John J Blenis

US Patent:

20130252950, Sep 26, 2013

Filed:

Sep 23, 2011

Appl. No.:

13/825723

Inventors:

John Blenis - Newtonville MA, US
Steven P. Gygi - Foxborough MA, US
Yonghao Yu - Roxbury MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C12Q 1/48
G01N 33/68

US Classification:

5142325, 435 15, 514291, 435 71, 506 9

Abstract:

Provided are over 300 mTOR kinase targets identified by a comprehensive phosphoproteomics assay. Methods of targeting mTOR kinase targets, methods to determine the level of mTOR activity by measuring the level of phosphorylation of an mTOR targeted phosphorylation site, methods for distinguishing different classes of mTOR activity in a cell based on phosphoproteomic analysis of mTOR-targeted proteins are also provided. Also provided is the classification of a hyperproliferative disease based on phosphoproteomic analysis of mTOR-targeted proteins, as well as the personalization of therapeutic methods for the treatment of hyperproliferative disease based on phosphoproteomics. Also provided are therapeutic methods including administering to a subject an mTOR inhibitor, an mTOR inhibitor and an additional kinase inhibitor, or a dual inhibitor of mTOR and an additional kinase based on the phosphorylation levels of mTOR targets determined in the subject. Some aspects of this invention relate to the discovery that GrblO is an mTOR-targeted tumor suppressor gene.

US Patent:

6372467, Apr 16, 2002

Filed:

Oct 29, 1999

Appl. No.:

09/430564

Inventors:

John Blenis - Roslindale MA
Calvin J. Kuo - Boston MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C12N 900

US Classification:

435194, 435183

Abstract:

Disclosed are novel mammalian kinases, p54 and p85. Also disclosed are methods for identifying compounds that modulate, or which are modulated by, p54 or p85. In addition, the invention discloses methods for diagnosing or treating a cellular proliferative disease.

US Patent:

20170184565, Jun 29, 2017

Filed:

Feb 12, 2015

Appl. No.:

15/116319

Inventors:

Thomas M. ROBERTS - Cambridge MA, US
Haoxuan TONG - Boston MA, US
Jean J. ZHAO - Brookline MA, US
John BLENIS - Newtonville MA, US
- Boston MA, US
- Cambridge MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

G01N 33/50
A61K 45/06
A61K 31/58
G01N 33/574
C12Q 1/68

Abstract:

The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.